Ipca Labs Q4FY21 performance was disappointing, but looking at the medium-term prospects, this appears to be an aberration. In spite of extraordinary sales of hydroxychloroquine in the last financial year, the company is expecting a 9-10 percent topline growth for FY22.
This is expected to be led by 16-18 percent domestic formulations growth which is backed by steady performance of pain management and recovery in acute therapies. However, in the case of APIs, the sales could be flat due to high base effect and capacity constraints. Although the sales could pick up meaningfully from FY23.
In the special segment ‘Moneycontrol Pro Ideas For Profit’, moneycontrol.com’s Anubhav Sahu gets more details on the company’s performance going forward.
Watch the video for more.Disclaimer: The views and investment tips expressed by investment experts on CNBCTV18.com are their own and not that of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.